Background: Upon engagement of the T cell receptor for antigen, its associated CD3 proteins recruit signal transduction molecules, which in turn regulate T lymphocyte proliferation, apoptosis, and thymocyte development. Because some signal transducing molecules re-
INTRODUCTION
Tumorigenesis involves perturbation of multiple signal transduction cascades resulting in a profound disturbance of normal control of cell cycling, cell growth, and/or cell death (1) (2) (3) . Whereas mutated oncogenes and tumor suppres-sor genes play a pivotal role in these processes (4) (5) (6) (7) (8) (9) , adapters of signal transduction pathways can also be tumorigenic (10) (11) (12) (13) (14) (15) . To investigate whether a surface receptor-associated protein that functions primarily by recruiting signal transduction molecules could also be tumorigenic, we analyzed large numbers of independently derived CD3-s transgenic mice for spontaneous development of T cell tumors. CD3-s is a T cell receptor (TCR)-associated membrane protein that plays a role in TCR/CD3 complex assembly and signal transduction (16) (17) (18) (19) (20) . Upon engagement of the T cell receptor with antigen, CD3-s directed signal transduction pathways are initiated that regulate T cell proliferation, apoptosis, and thymocyte development (21) (22) (23) (24) (25) . Because some signal transducing molecules recruited by CD3-s, i.e., p56lCk and p591fy, are oncogenic (26, 27) , a disturbance of CD3-s signaling could potentially lead to abnormal T lymphocyte death and lymphomagenesis.
As previously reported in a number of independently derived homozygous CD3-s transgenic mice (i.e., tgs26+1+), a very early block in thymocyte and natural killer (NK) cell development is observed. This block in development is caused by overexpression of the CD3-s proteins derived from the transgenes that are regulated by their own cis-regulatory elements (28, 29 ). Here we demonstrate that in hemizygous transgenic mouse lines, overexpression of CD3-E resulted in an extremely high incidence of very aggressive T cell lymphomas. The 
MATERIALS AND METHODS

Mice
Generation and screening of transgenic mice carrying all DNA constructs were carried out as described previously (28, 29 4 weeks later.
Histology
Tissues were frozen at -20°C and mounted for cryostat sectioning. Sections 5 ,um thick were fixed in 4% paraformaldehyde, phosphate-buffered saline (PBS) (pH 7.4). The sections were stained with hematoxylin and eosin, or used for immunohistochemistry as described below. The sections were blocked with 2% normal rat serum, PBS (pH 7.4) for 20 min, stained with biotinylated primary antibodies for 1 Mice that were hemizygous for the same transgenes were only partially T cell deficient even though the homozygous counterparts had a complete developmental block. n.d., not determined; wt: wild type.
aCopy number refers to the copy number of transgenes in a hemizygous mouse (28) .
bTotal number of thymocytes as % of those in wild-type litter mates (28) .
cThe frequency was obtained as described in the Methods. were analyzed. In young (4 to 6 weeks) RAG2nu1l X tgsA1-2966H+'-mice, the transgene in- Tumors from Lcknull X tge26+1 mice. duced a transition from DN to DP (CD4+8+) thymocytes, along with down-regulation of CD2 5, and a moderate increase in cellularity (Fig. 5, Table 3 ). In RAG-2 null x tgs26+' and RAG_2null X tgsA1-2966H+/+ mice, a similar transition of DN to DP thymocytes and the down-regulation of CD25 were observed (Table 3 ). In the latter mice, however, the thymocyte cellularity was lower than in the antibody-induced transition, most likely because of the apoptosis of early thymocytes ( (23) . However, lcknull X tgs26+-double mutant mice developed lymphomas at a high frequency (Table 3 and Fig. 4b ). Taken together, these analyses on double mutant mice shown in Table 3 (38) . However, there are some differences between these systems. We demonstrated that Ick is not essential for CD3-s induced T cell lymphomas, because both CD3+ and CD3-tumor cells were observed in the double mutant lcknull X tgs26+1 mice. In contrast, only CD3-tumors were found in the transgenic mice overexpressing lck (26) . In hemizygous Ikaros mutant mice, T cell lymphomagenesis is preceded by a lymphoproliferation in thymocytes and peripheral T cells (38) . This phenomenon was not observed in thymocytes and peripheral T cells derived from prelymphoma tgs26+'-mice.
We propose that overexpression of CD3-s generates a signal to induce cell transformation, and we further postulate that the signal is related to normal signal transduction through CD3-s. This hypothesis is supported by the observation that overexpression of CD3-s mimics the effects induced by anti-CD3-s treatment of thymocytes in vivo (23, 31) . For instance, overexpression of CD3-s in thymocytes prevents intracellular TCR-,3 expression, induces apoptosis (29; D. Zheng et al., unpublished observations), and induces a transition from DN to DP in RAG-2null mice. Moreover, this hypothesis is consistent with earlier reports suggesting that murine leukemia virus-induced leukemogenesis is mediated through a signal(s) triggered by the binding of the virus with T cell receptors (39, 40) . Signal transduction through CD3-s involves Ick and other c-src-like kinases (20, 41, 42) . Although Ick is dispensable for CD3-s-induced T cell lymphomas, it is still conceivable that induction of T cell tumorigenesis by CD3-s and Ick share common downstream pathways. Importantly, unlike Ick, the 55 amino acid cytoplasmic tail of CD3-E is not a protein tyrosine kinase, nor does it have any known enzymatic activity. The role of CD3-s in oncogenesis may therefore lie in its function as a provider of docking sites for kinases and other signal transduction enzymes. There may be some similarity with nonenzymatic adapter proteins. This notion is consistent with recent observations that Shc, one of the nonenzymatic adapter proteins involved in a variety of signal transduction pathways, can induce cell transformation in in vitro culture systems (10) (11) (12) (13) (14) (15) . Nonenzymatic receptor proteins other than CD3-s may therefore be potential oncogenes under some circumstances.
